Medicines and ethics
Poor-quality medicines are especially prevalent in low- and middle-income countries. They represent a threat for individual and public health. Tragically, they often go undetected, or they are detected after treatment failure or toxicity become evident. ‘Repressive’ measures may help fight falsified medicines, but they will do little to stop the circulation of substandard medicines, which requires sustained capacity strengthening of regulators, manufacturers and purchasers.
ITM manages a scientific portfolio focusing on access to quality-assured medicines in low- and middle-income countries, in close collaboration with the QUAMED group. Our specific activities include policy development, research, advocacy, networking and education
Clinical trials are more and more delocalised to low- and middle-income countries, often for global health reasons (to address the local health needs). It is of paramount importance that all these trials are methodologically and ethically sound, and responsive to the needs of communities.
We animate the informal network of clinical researchers that previously operated under the frame of the Switching the Poles Network. We stimulate exchange of view, scientific collaborations and ethical reflection.